Alexion Pharmaceuticals, Inc . ALXN announced that it will undertake a restructuring plan to re-align the organization with refocused corporate strategy.
Details of Restructuring
The company plans to focus on rare diseases businesses in core areas of hematology, nephrology, neurology and metabolic disorders to enhance productivity. Alexion will reduce spending and headcount associated with the previously announced de-prioritized pipeline programs as well as optimizing additional R&D expenses.
The three programs which have been deprioritized are – ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab) as well as partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma ABUS .
Read the full article at: http://www.nasdaq.com/article/alexion-to-restructure-operations-to-lower-headcount-by-20-cm845425